


03CO  
#17

TRANSMITTAL LETTER			Case No. 11509/8
Serial No. 09/978,344	Filing Date October 16th, 2001	Examiner Not assigned	Group Art Unit Not assigned
Inventor(s) Dennis et al.			
Title of Invention Detoxification and Decontamination Using Nanotechnology Therapy			



TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is IDS, PTO Form 1449, Cited References; Return post card.

- ☒ Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.
- ☐ Petition for a \_\_\_\_\_ month extension of time.
- ☒ No additional fee is required.
- ☐ The fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total		Minus		
Indep.		Minus		
First Presentation of Multiple Dep. Claim				

Small Entity		or	Other Than Small Entity	
Rate	Add'l Fee		Rate	Add'l Fee
x \$9 =			x \$18 =	
x 42 =			x \$84 =	
+ \$140 =			+ \$280 =	
Total add'l fee	\$		Total add'l fee	\$

- ☐ Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ \_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
- ☒ I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

John Murray  
John Murray  
Registration No. 44,251  
Attorney for Applicant

BRINKS HOFER GILSON & LIONE  
P.O. BOX 10395  
CHICAGO, ILLINOIS 60610  
(312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on September 27<sup>th</sup>, 2002.

Date: SEPTEMBER 27<sup>th</sup>, 2002 Signature: John Murray

I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, D.C. 20231

on SEPTEMBER 27<sup>th</sup>, 2002

Date of Deposit

JOHN MURRAY


Name of applicant, assignee or  
Registered Representative

John Murray

Signature

SEPTEMBER 27<sup>th</sup>, 2002

Date of Signature



Case No. 11509/8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dennis et al.

Serial No: 09/978344

Filed: October 16<sup>th</sup>, 2001

For: Detoxification and Decontamination  
Using Nanotechnology Therapy

Examiner: Not assigned

Group Art Unit: 1614

**FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this First Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

It is believed that this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the following cited documents are enclosed:

B1	U.S. 5,993,831	Nov 30, 1999	Ribier
B2	U.S. 5,990,373	Nov 23, 1999	Klabunde
B3	U.S. 5,914, 436	Jun 22, 1999	Klabunde
B4	U.S. 6,057,488	May 2, 2000	Koper

B5	WO 00/47236 A1		PCT
B6	WO 01/17648 A1		PCT
B7	WO 00/4736 A1 (corrected)		PCT
B8	DE 198 25 856 A1		Germany

B9	Koper et al., <i>Development of Reactive Topical Skin Protectants against Sulfur Mustard and Nerve Agents</i> , J Appl. Toxicol. 19, S59 – S70 (1999)		
B10	Gill and Ballesteros, Degradation of Organophosphorous Nerve Agents by Enzyme-Polymer Nanocomposites: Efficient Biocatalytic Materials for Personal Protection and Large-Scale Detoxification, <i>Biotechnology and Bioengineering</i> vol. 70, no. 4, pp 400 – 410 (2000)		
B11	International Search Report for PCT/US02/06114		

The above documents, including German patent DE 198 25 856 A1, were contained in a PCT International Search Report. No English language equivalent is available for the German patent.

If, for any reason, the Examiner feels that an interview would be helpful to resolve any issues, he is respectfully requested to contact the undersigned attorney at (312) 321-4229.

Respectfully submitted,


Date: SEPTEMBER 27<sup>th</sup>, 2002 .

John Murray  
John Murray, Ph.D.  
Registration No. 44,251  
Attorney for Applicant

BRINKS HOFER GILSON & LIONE  
P.O. Box 10395  
Chicago, IL 60610  
(312) 321-4200

### **INSTRUCTIONS**

**This Information Disclosure Statement (IDS) is sent in with the PTO form 1449. If this is a first IDS in a file, refer to it throughout as “Information Disclosure Statement.” If this is an IDS subsequent to the first IDS in a file, refer to it throughout as “First Supplemental Information Disclosure Statement,” “Second Supplemental Information Disclosure Statement,” “Third Supplemental Information Disclosure Statement,” etc. Also, on the Form PTO-1449, Label references with a Prefix “A” for the first filed IDS, “B” for the First Supplemental IDS, “C” for the Second Supplemental IDS, “D” for the Third Supplemental IDS, etc.**



FORM PTO-1449	SERIAL NO. 09/978,344	CASE NO. 11509/8
<b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>	FILING DATE October 16 <sup>th</sup> , 2001	GROUP ART UNIT 1614
(use several sheets if necessary)		APPLICANT(S): Dennis et al.

#### REFERENCE DESIGNATION

#### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	B1	U.S. 5,993,831	Nov 30, 1999	Ribier		
	B2	U.S. 5,990,373	Nov 23, 1999	Klabunde		
	B3	U.S. 5,914, 436	Jun 22, 1999	Klabunde		
	B4	U.S. 6,057,488	May 2, 2000	Koper		

#### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES	NO
	B5	WO 00/47236 A1		PCT			
	B6	WO 01/17648 A1		PCT			
	B7	WO 00/4736 A1 (corrected)		PCT			
	B8	DE 198 25 856 A1		Germany			

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
	B9	Koper et al., <i>Development of Reactive Topical Skin Protectants against Sulfur Mustard and Nerve Agents</i> , J Appl. Toxicol. 19, S59 – S70 (1999)
	B10	Gill and Ballesteros, <i>Degradation of Organophosphorous Nerve Agents by Enzyme-Polymer Nanocomposites: Efficient Biocatalytic Materials for Personal Protection and Large-Scale Detoxification</i> , Biotechnology and Bioengineering vol. 70, no. 4, pp 400 – 410 (2000)
	B11	International Search Report for PCT/US02/06114

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.